



TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9th Floor, Bigios Tower, Netaji Subhash Place, Delhi-110034, India
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

To,
Corporate Services Department,
BSE Ltd.,
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai-400001

Date: 04/02/2023

Scrip Code: 524717

Sub: Outcome of Board Meeting

Dear Sir/Ma'am,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. **Saturday, 4th February, 2023**, at their Office, inter-alia approved the Standalone and Consolidated Unaudited Financial Results for the **Quarter and Nine Months ended on 31st December, 2022**.

In terms of the Provisions of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the following:

1. **Unaudited Financial Results** for the Quarter and Nine Months ended on **31st December, 2022**.
2. **Limited Review Report** on the Unaudited Financial Results for the Quarter and Nine Months ended on **31st December, 2022**.

The meeting commenced at **03.00 P.M.** and concluded at **03.50 P.M.**

The above information will be available on the website of the Company i.e. <https://titanbiotechltd.com/>.

**Thanking You,
For Titan Biotech Limited**


Charanjit Singh
Company Secretary
M.No A12726



Encl. as above

R.O. & Works: Unit I: A-902 A, RIICO Industrial Area, Phase-III, Bhiwadi-301019, Rajasthan

Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: marketing@titanbiotechltd.com

Website: www.titanbiotechltd.com | www.titanmedia.in



A N S K & Associates

CHARTERED ACCOUNTANTS

**OFFICE : 414, RG Trade Tower, Netaji Subhash Place,
Pitampura, Delhi-110034**

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

Independent Auditor's Review Report on Quarterly and year to date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

THE BOARD OF DIRECTORS
TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Titan Biotech Limited (the "Company"), for the quarter ended December 31, 2022 and the year to date results for the period 1st April 2022 to 31 December 2022 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 193 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

A N S K & Associates

CHARTERED ACCOUNTANTS

**OFFICE : 414, RG Trade Tower, Netaji Subhash Place,
Pitampura, Delhi-110034**

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. Other Matter

The Statement includes comparative financial results of the Company for the corresponding quarter and nine month ended December 31, 2021 which have been reviewed by the predecessor audit firm, where they have expressed an unmodified conclusion vide report dated February 09, 2022. The Statement also includes financial results for the year ended March 31, 2022, which have been audited by the predecessor audit firm, where they have expressed an unmodified opinion vide report dated May 30, 2022.

Our conclusion is not modified in respect of this matter.

For A N S K & Associates

Chartered Accountants

Firm's Registration No. 026177N

Akhil

Mittal

(CA Akhil Mittal)

Partner

M.No. 517856

Date: 04.02.2023

Place: New Delhi

UDIN: 23517856BGUXEY3736

Digitally signed by Akhil Mittal
DN: c=IN, st=Delhi,
2.5.4.20=06581c3c79d10735b86d0dc8a4e193c1d8f5
ee1f1daa6aeaf56f853f482, postalCode=110026,
street=FAST PUNJABI BAGH, Punjabi Bagh , West Delhi,
pseudoDn=8e5017d2da4c47c3b50c907d67942a2ef,
serialNumber=6542737f71ae0c64179cf29da06b125f
7e4d7e8f1d1b7b3b6c40646289, o=Personal,
cn=Akhil Mittal
Date: 2023.02.04 15:47:19 +05'30'



A N S K & Associates

CHARTERED ACCOUNTANTS

**OFFICE : 414, RG Trade Tower, Netaji Subhash Place,
Pitampura, Delhi-110034**

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

Independent Auditor's Review Report on Quarterly and Year to date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

THE BOARD OF DIRECTORS
TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Titan Biotech Limited (the "Company") and its Associates, for the quarter ended December 31, 2022 and the consolidated year to date results for the period from 1 April 2022 to 31 December 2022 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 193 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 414, RG Trade Tower, Netaji Subhash Place,
Pitampura, Delhi-110034

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

-
4. The Statement includes results of the Holding Company -Titan Biotech Limited and Associate Company - Peptech Biosciences Limited.
 5. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of its associates which have been approved and furnished to us by the management. Our Conclusion on the statement is not modified in respect of the above matter.
 6. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
 7. The unaudited consolidated financial results also includes the Group's share of net profit after tax of Rs.42.01 lacs and 262.81 lacs and total comprehensive income of Rs.42.01 Lacs and Rs. 262.81 lacs for the quarter and nine month ended 31st December 2022, respectively, as considered in the consolidated unaudited financial results, in respect of one Associate, based on their interim financial results which have not been reviewed/audited by their Auditor. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a associate, are based solely on such unaudited interim financial results. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.
Our conclusion is not modified in respect of this matter.
 8. **Other Matter**

The Statement includes comparative consolidated financial results of the Company for the corresponding quarter and nine month ended December 31, 2021 which have been reviewed by the predecessor audit firm, where we have expressed an unmodified conclusion vide report dated 9th February 2022. The Statement also includes financial results for the year ended March 31, 2022, which have been audited by the predecessor audit firm, where they have expressed an unmodified opinion vide report dated May 30, 2022.

Our conclusion is not modified in respect of this matter.



A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 414, RG Trade Tower, Netaji Subhash Place,

Pitampura, Delhi-110034

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

For A N S K & Associates

Chartered Accountants

Firm's Registration No. 026177N

Akhil Mittal

Digitally signed by Akhil Mittal
DN: c=IN, o=CA, ou=CA, email=akhil.mittal@ansk.co.in, postalCode=110026, street=FAST PUNJABI
BAGH, Punjab, India, serialNumber=45427770, serialNumber=17952726406612352746748
d1d37f8b6c6c46f46289, cn=Akhil Mittal
Date: 2022.02.04 15:45:43 +05'30'

(CA Akhil Mittal)

Partner

M.No. 517856

Date: 04.02.2022

Place: New Delhi

UDIN: 23517856BGUXEZ1090

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER, 2022

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	STANDALONE					
		QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED	
		31.12.2022 UNAUDITED	30.09.2022 UNAUDITED	31.12.2021 UNAUDITED	31.12.2022 UNAUDITED	31.12.2021 UNAUDITED	31.03.2022 AUDITED
1	INCOME						
	Revenue from operations	3,033.30	4,183.38	2,896.88	10,716.30	9,246.22	12,354.89
	Other Income	27.85	85.64	18.82	145.13	56.00	94.13
	Total Income	3,061.15	4,269.02	2,915.70	10,861.43	9,302.22	12,449.02
2	EXPENSES						
	Cost of Materials Consumed	1,389.55	2,178.59	1,498.98	5,352.53	4,465.68	5,912.24
	Changes in inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	3.60	(44.93)	(48.86)	(102.06)	19.11	(17.30)
	Employee Benefit Expenses	466.66	452.21	349.80	1,298.82	1,011.70	1,433.00
	Finance Costs	14.26	17.03	17.51	48.88	60.58	78.39
	Depreciation and Amortization Expenses	64.74	63.76	57.23	188.95	167.71	236.91
	Other Expenses	759.57	549.38	449.46	1,898.32	1,322.11	1,908.88
	Total Expenses	2,698.38	3,216.04	2,324.12	8,685.44	7,046.89	9,552.12
3	Profit/(loss) before exceptional items and tax (1-2)	362.77	1,052.98	591.58	2,175.99	2,255.33	2,896.90
4	Exceptional Items	-	-	-	-	-	-
5	Profit/ (loss) before tax (3+4)	362.77	1,052.98	591.58	2,175.99	2,255.33	2,896.90
6	Tax expense:						
	I) Current Tax	93.04	268.61	145.27	543.51	559.72	735.07
	II) Deferred Tax	(0.46)	(2.41)	3.57	(2.22)	7.49	(6.57)
	(III) Earlier year taxes	-	(3.43)	(0.02)	(3.43)	(0.02)	(0.03)
	Total Tax (I+II)	92.58	262.77	148.82	537.86	567.19	728.47
7	Profit (Loss) for the period after Tax (5-6)	270.19	790.21	442.76	1,638.13	1,688.14	2,168.43
8	Other comprehensive income (Net of Tax)						
A.	Items that will not be reclassified to profit or loss						
	Re-measurement gain on defined benefit plans	-	-	-	-	-	(2.08)
B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income for the period (A+B)(net of taxes)	-	-	-	-	-	(2.08)
9	Total Comprehensive Income for the period (7+8)	270.19	790.21	442.76	1,638.13	1,688.14	2,166.35
10	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37	826.37	826.37
11	Other Equity	-	-	-	-	-	7,798.04
12	Earnings per equity share (face value of Rs.10/- each) not annualised						
	(1) Basic	3.27	9.56	5.36	19.82	20.43	26.24
	(2) Diluted	3.27	9.56	5.36	19.82	20.43	26.24

Notes:

- The above unaudited standalone financial results for the quarter and nine months ended on 31.12.2022 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on February 04, 2023. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and nine months ended on 31st Dec. 2022 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The total sale for the quarter ended 31.12.2022 includes sale of Products of Rs. 1.47 Lakhs the demand for which arose due to Covid 19 Pandemic.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448



Place : Delhi
Dated : 04.02.2023

TITAN BIOTECH LIMITED
 Regd. Office :- A-902 A RHICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019
 Phone No. 011- 71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387
STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER, 2022
 (Rs. IN LAKHS) except for EPS

Sr. No.	PARTICULARS	STANDALONE					
		QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	Total Income from Operations (Net)	3,061.15	4,269.02	2,915.70	10,861.43	9,302.22	12,449.02
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	362.77	1,052.98	591.58	2,175.99	2,255.33	2,896.90
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	362.77	1,052.98	591.58	2,175.99	2,255.33	2,896.90
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	270.19	790.21	442.76	1,638.13	1,688.14	2,168.43
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income (after tax) (refer note 3)	270.19	790.21	442.76	1,638.13	1,688.14	2,166.35
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	-	-	7,798.04
8	Earning Per Share (of INR 10/- each)						
	(a) Basic	3.27	9.56	5.36	19.82	20.43	26.24
	(b) Diluted	3.27	9.56	5.36	19.82	20.43	26.24


NOTES :

- The above is an extract of the detailed format of standalone Unaudited Financial Results for the quarter and nine months ended on 31.12.2022 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone Unaudited Financial Results for the said quarter and nine months ended on 31.12.2022 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com. The statutory auditors of the company have carried out a limited review of the aforesaid results.
- The above unaudited standalone financial results for the quarter and nine months ended on 31.12.2022 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on February 04, 2023. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and nine months ended on 31.12.2022 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The total sale for the quarter ended 31.12.2022 includes sale of Products of Rs. 1.47 Lakhs the demand for which arose due to Covid 19 Pandemic.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

Place : Delhi
 Dated : 04.02.2023

For and on behalf of Board of Directors
 for TITAN BIOTECH LIMITED

Naresh Kumar Singla
 NARESH KUMAR SINGLA
 Managing Director
 DIN-00027448



TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239980, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER, 2022

(Rs. IN LAKHS) except for EPS


Sr. No	PARTICULARS	CONSOLIDATED					
		QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	INCOME						
	Revenue from operations	3,033.30	4,183.38	3,642.69	10,716.30	11,987.38	15,280.97
	Other Income	27.85	85.64	22.83	145.13	62.84	102.25
	Total Income	3,061.15	4,269.02	3,665.52	10,861.43	12,050.22	15,383.22
2	EXPENSES						
	Cost of Materials Consumed	1,389.55	2,178.59	1,908.19	5,352.53	6,007.34	7,547.79
	Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	3.60	(44.93)	(44.65)	(102.06)	(22.84)	(60.16)
	Employee Benefit Expenses	466.66	452.21	406.57	1,298.82	1,170.84	1,613.74
	Finance Costs	14.26	17.03	34.02	48.88	107.92	128.26
	Depreciation and Amortization Expenses	64.74	63.76	62.44	188.95	183.29	253.84
	Other Expenses	759.57	549.38	503.41	1,898.32	1,474.49	2,079.92
	Total Expenses	2,698.38	3,216.04	2,869.98	8,685.44	8,921.04	11,563.39
3	Profit/(loss) before exceptional items and tax (1-2)	362.77	1,052.98	795.54	2,175.99	3,129.18	3,819.83
4	Exceptional Items	-	-	-	-	-	-
5	Profit/ (loss) before tax (3+4)	362.77	1,052.98	795.54	2,175.99	3,129.18	3,819.83
6	Tax expense:						
	I) Current Tax	93.04	268.61	196.87	543.51	780.67	970.33
	II) Earlier year taxes	(0.46)	(1.76)	1.45	(2.22)	1.69	1.69
	III) Deferred Tax	-	(4.08)	3.32	(3.43)	6.47	(7.50)
	Total Tax (I+II)	92.58	262.77	201.64	537.86	788.83	964.52
7	Profit (Loss) for the period after Tax (5-6)	270.19	790.21	593.90	1,638.13	2,340.35	2,855.31
8	Share in Profit of Associate	55.97	122.48	-	351.17	-	19.03
9	Profit (Loss) for the period (7+8)	326.16	912.69	593.90	1,989.30	2,340.35	2,874.34
10	other comprehensive income (Net of Tax)						
A.	Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	Re-measurement gain on defined benefit plans	-	-	-	-	-	(2.08)
(i)	Items that will be reclassified to profit or loss	-	-	-	-	-	-
B	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income for the period (A+B)(net of taxes)	-	-	-	-	-	(2.08)
11	Total Comprehensive Income for the period (7+8)	326.16	912.69	593.90	1,989.30	2,340.35	2,872.26
12	Net profit attributable to:						
	Owners of the holding company	-	-	523.05	-	2,034.60	2,533.30
	Non-controlling interest	-	-	70.86	-	305.76	322.01
13	Other comprehensive income attributable to :						
	Owners of the holding company	-	-	-	-	-	(1.71)
	Non-controlling interest	-	-	-	-	-	(0.37)
14	Total Comprehensive Income attributable to (10+11)						
	Owners of the holding company	-	-	523.05	-	2,034.60	2,531.59
	Non-controlling interest	-	-	70.86	-	305.76	321.64
15	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37	826.37	826.37
16	Other Equity	-	-	-	-	-	9,040.49
17	Earnings per equity share (face value of Rs 10/- each) not annualised						
(1)	Basic	3.95	11.04	6.33	24.07	24.62	30.66
(2)	Diluted	3.95	11.04	6.33	24.07	24.62	30.66

Notes:

- The above consolidated unaudited financial results for the quarter and nine months ended on 31.12.2022 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on February 04, 2023. The statutory auditors of the company have carried out a limited review of the aforesaid results. The results for the quarter and nine months ended Dec 31, 2022, are available on the BSE Limited website(bseindia.com) and on the company's Website(titanbiotechltd.com)
- The consolidated unaudited financial results for the quarter and nine months ended on 31.12.2022 include the results of following:-
Associate Company - Peptech Biosciences Limited
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and nine months ended on 31 Dec. 2022 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The total sale for the quarter ended 31.12.2022 includes sale of Products of Rs. 1.47 Lakhs the demand for which arose due to Covid 19 Pandemic.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448



Place : Delhi
Dated : 04.02.2023

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER, 2022

(Rs. IN LAKHS) except for EPS


S.NO.	PARTICULARS	CONSOLIDATED					
		QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	Total Income from Operations (Net)	3,061.15	4,269.02	3,665.52	10,861.43	12,050.22	15,383.22
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	362.77	1,052.98	795.54	2,175.99	3,129.18	3,819.83
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	362.77	1,052.98	795.54	2,175.99	3,129.18	3,819.83
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	326.16	912.69	593.90	1,989.30	2,340.35	2,874.34
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income (after tax) (refer note 3)	326.16	912.69	593.90	1,989.30	2,340.35	2,872.26
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	-	-	9,040.49
8	Earning Per Share (of INR 10/- each)						
	(a) Basic	3.95	11.04	6.33	24.07	24.62	30.66
	(b) Diluted	3.95	11.04	6.33	24.07	24.62	30.66

NOTES :

- The above is an extract of the detailed format of consolidated Unaudited Financial Results for the quarter and nine months ended on 31.12.2022 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the consolidated unaudited Financial Results for the said quarter and nine months ended on 31st Dec. 2022 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above consolidated unaudited financial results for the quarter and nine months ended on 31.12.2022 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on February 04, 2023. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and nine months ended on 31.12.2022 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The total sale for the quarter ended 31.12.2022 includes sale of Products of Rs. 1.47 Lakhs the demand for which arose due to Covid 19 Pandemic.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED


NARESH KUMAR SINGLA
Managing Director
DIN-00027448



Place : Delhi
Dated : 04.02.2023